Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Focus Pharmaceuticals Ltd, Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom
Clindamycin 150mg/ml Solution for Injection or Infusion.
| Pharmaceutical Form |
|---|
|
Solution for Injection or Infusion. Clear, colourless, solution. |
Each 1ml of solution contains clindamycin phosphate equivalent to 150mg clindamycin.
Each 2ml ampoule contains 300mg clindamycin.
Each 4ml ampoule contains 600mg clindamycin.
Excipients: Sodium 6.57mg per ml (prior to dilution).
For a full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis. |
| List of Excipients |
|---|
|
Disodium edetate |
Type 1 flint glass ampoule containing 2ml or 4ml sterile, aqueous solution, packed in cardboard carton, together with a leaflet. 1 or 5 ampoules in each pack.
Not all pack sizes may be marketed.
Focus Pharmaceuticals Ltd, Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom
PL 20046/0072
11/01/2010
| Drug | Countries | |
|---|---|---|
| CLINDAMYCIN | Nigeria |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.